Saturday 17 October 2026
Export MLYS’s income statement to Excel — free account
Mineralys Therapeutics, Inc.
MLYS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 331.8% and free cash flow fell 7.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
20.30
1.34
−6.19%
Follow MLYS
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 5.85 | 7.95 | 8.24 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 21.98 | 16.91 | 47.65 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 12 | 12 | 28 | 51 | 76 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | (3) | (19) | (30) | (72) | (178) | (155) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | (3) | (19) | (30) | (72) | (178) | (155) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (0.74) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) | |||||
| Cash flow | — | — | — | — | (0.53) | (2.92) | (5.66) | (2.24) | (3.43) | (2.10) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | (0.53) | (2.92) | (5.66) | (2.24) | (3.43) | (2.11) | |||||
| Book value | — | — | — | — | (0.78) | (4.60) | (10.12) | 6.66 | 3.94 | 9.56 | |||||
| Shares, m | — | — | — | — | 5 | 5 | 5 | 36 | 49 | 68 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (2) | (15) | (29) | (81) | (166) | (142) | ||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Free cash flow | — | — | — | — | (2) | (15) | (29) | (81) | (166) | (142) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (4) | 6 | 105 | 239 | 191 | 646 | ||||
| Total debt | — | — | — | — | 5 | — | — | — | — | — | |||||
| Net debt | — | — | — | — | (1) | (11) | (110) | (237) | (198) | (657) | |||||
| Shareholders’ equity | — | — | — | — | (4) | (23) | (52) | 241 | 191 | 647 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (307.79) | (47.46) | (39.28) | (77.72) | (35.65) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (1,153.49) | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 0.00 | 146.35 | 79.26 | (76.13) | (82.24) | (36.91) | |||||
Negative figures in brackets.
Charts ten years each
Mineralys Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LKFT Lakefront Biotherapeutics - Sponsored ADR | $2.0B | — (loss-making) | — (loss-making) | −95.35% (below 0%: shrinking) | +198.85% (above 0%: growing) | +18.22% (above 0%: growing) | 25.95% | (982.91%) | Compare |
| AGIO Agios Pharmaceuticals, Inc. | $1.9B | — (loss-making) | — (loss-making) | +259.25% (above 0%: growing) | n/m | +24.97% (above 0%: growing) | 93.30% | (247.07%) | Compare |
| MLYS Mineralys Therapeutics, Inc. | $1.9B | — (loss-making) | — | — | n/m | −7.91% (below 0%: shrinking) | — | 0.00% | |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | — (loss-making) | 4.4× | −34.34% (below 0%: shrinking) | n/m | −14.48% (below 0%: shrinking) | 62.77% | 3.31% | Compare |
| MRVI Maravai LifeSciences Holdings, Inc. | $1.8B | — (loss-making) | — (loss-making) | +8.53% (above 0%: growing) | n/m | +127.57% (above 0%: growing) | 40.14% | (29.33%) | Compare |
| ZYME Zymeworks Inc. | $1.8B | — (loss-making) | 16.2× | −90.58% (below 0%: shrinking) | n/m | −385.53% (below 0%: shrinking) | (497.71%) | (918.95%) | Compare |
| PVLA Palvella Therapeutics, Inc. | $1.8B | — (loss-making) | — (loss-making) | −99.09% (below 0%: shrinking) | n/m | −136.38% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MESO Mesoblast Limited | $1.8B | — (loss-making) | — | −13.41% (below 0%: shrinking) | n/m | −89.23% (below 0%: shrinking) | (353.35%) | (909.40%) | Compare |
| URGN Urogen Pharma | $1.8B | — (loss-making) | — (loss-making) | +199.22% (above 0%: growing) | n/m | +17.26% (above 0%: growing) | 90.93% | 0.15% | Compare |
| Median of peers | $1.8B | — | — | −23.87% | — | +1.39% | 51.46% | (138.20%) |
Mineralys Therapeutics, Inc. (MLYS) key facts
- Mineralys Therapeutics, Inc. (MLYS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MLYS traded at $20.30, a market capitalization of $1.9 billion.
- Return on equity was −36.9% and debt-to-equity 0.18.